Cancer de prostate métastatique résistant à la castration : le point de vue de l’oncologue médical,10.1016/j.mednuc.2011.04.003,Medecine Nucleaire-ima

Cancer de prostate métastatique résistant à la castration : le point de vue de l’oncologue médical


	BibTex \| RIS \| RefWorks Download

, , ,

Most of patient suffering from a prostate cancer will develop a castration resistance. In this common and clinically challenging situation, chemotherapy was not considered very useful until mid 2000s. Docetaxel is now recognized as a standard of care, improving overall survival and quality of life. However, new drugs are needed. Two compounds (cabazitaxel and abiraterone) are now underway to official registration and an autologous vaccin strategy (Sipuleucel) demonstrated a benefit in survival. Based on a greater knowledge of biology, many other agents are currently under development, such as new specific peripheral anti-androgens, anti-angiogenic therapies, or proteasome inhibitors. All these new drugs are promising and may provide more efficient therapies against this incurable disease in the near future.

Journal: Medecine Nucleaire-imagerie Fonctionnelle Et Metabolique - MED NUCL , vol. 35, no. 6, pp. 378-383, 2011

DOI: 10.1016/j.mednuc.2011.04.003

Cumulative Annual

View Publication

( www.sciencedirect.com )


	The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.

Keywords (5)

Cancer de prostate métastatique résistant à la castration : le point de vue de l’oncologue médical,10.1016/j.mednuc.2011.04.003,Medecine Nucleaire-ima